| An inflammatory cytokine signature predicts COVID-19 severity and survival DM Del Valle, S Kim-Schulze, HH Huang, ND Beckmann, S Nirenberg, ... Nature medicine 26 (10), 1636-1643, 2020 | 2289 | 2020 |
| Oral selinexor–dexamethasone for triple-class refractory multiple myeloma A Chari, DT Vogl, M Gavriatopoulou, AK Nooka, AJ Yee, CA Huff, ... New England Journal of Medicine 381 (8), 727-738, 2019 | 600 | 2019 |
| Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations B Will, L Zhou, TO Vogler, S Ben-Neriah, C Schinke, R Tamari, Y Yu, ... Blood, The Journal of the American Society of Hematology 120 (10), 2076-2086, 2012 | 255 | 2012 |
| Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS L Barreyro, B Will, B Bartholdy, L Zhou, TI Todorova, RF Stanley, ... Blood, The Journal of the American Society of Hematology 120 (6), 1290-1298, 2012 | 231 | 2012 |
| Efficacy of transfusion with granulocytes from G-CSF/dexamethasone–treated donors in neutropenic patients with infection TH Price, M Boeckh, RW Harrison, J McCullough, PM Ness, RG Strauss, ... Blood, The Journal of the American Society of Hematology 126 (18), 2153-2161, 2015 | 224 | 2015 |
| Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma O Van Oekelen, CR Gleason, S Agte, K Srivastava, KF Beach, A Aleman, ... Cancer Cell 39 (8), 1028-1030, 2021 | 207 | 2021 |
| Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC … K Dunleavy, MA Fanale, JS Abramson, A Noy, PF Caimi, S Pittaluga, ... The Lancet Haematology 5 (12), e609-e617, 2018 | 185 | 2018 |
| BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms S Parekh, JM Polo, R Shaknovich, P Juszczynski, P Lev, SM Ranuncolo, ... Blood, The Journal of the American Society of Hematology 110 (6), 2067-2074, 2007 | 174 | 2007 |
| HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL M Kalac, L Scotto, E Marchi, J Amengual, VE Seshan, G Bhagat, ... Blood, The Journal of the American Society of Hematology 118 (20), 5506-5516, 2011 | 173 | 2011 |
| Discovery of a first-in-class EZH2 selective degrader A Ma, E Stratikopoulos, KS Park, J Wei, TC Martin, X Yang, M Schwarz, ... Nature chemical biology 16 (2), 214-222, 2020 | 168 | 2020 |
| Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma VV Leshchenko, PY Kuo, R Shaknovich, DT Yang, T Gellen, A Petrich, ... Blood, The Journal of the American Society of Hematology 116 (7), 1025-1034, 2010 | 166 | 2010 |
| A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward B Wang, O Van Oekelen, TH Mouhieddine, DM Del Valle, J Richter, ... Journal of hematology & oncology 13, 1-12, 2020 | 142 | 2020 |
| Stage-specific human induced pluripotent stem cells map the progression of myeloid transformation to transplantable leukemia AG Kotini, CJ Chang, A Chow, H Yuan, TC Ho, T Wang, S Vora, ... Cell stem cell 20 (3), 315-328. e7, 2017 | 142 | 2017 |
| Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome B Will, M Kawahara, JP Luciano, I Bruns, S Parekh, CL Erickson-Miller, ... Blood, The Journal of the American Society of Hematology 114 (18), 3899-3908, 2009 | 139 | 2009 |
| Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis CJ Heuck, J Mehta, T Bhagat, K Gundabolu, Y Yu, S Khan, G Chrysofakis, ... The Journal of Immunology 190 (6), 2966-2975, 2013 | 127 | 2013 |
| A critical role for Fas-mediated off-target tumor killing in T-cell immunotherapy R Upadhyay, JA Boiarsky, G Pantsulaia, J Svensson-Arvelund, MJ Lin, ... Cancer discovery 11 (3), 599-613, 2021 | 121 | 2021 |
| Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy O Van Oekelen, A Aleman, B Upadhyaya, S Schnakenberg, D Madduri, ... Nature medicine 27 (12), 2099-2103, 2021 | 120 | 2021 |
| A phase I study of a combination of anti‐CD19 and anti‐CD22 immunotoxins (Combotox) in adult patients with refractory B‐lineage acute lymphoblastic leukaemia J Schindler, S Gajavelli, F Ravandi, YM Shen, S Parekh, I Braunchweig, ... British journal of haematology 154 (4), 471-476, 2011 | 114 | 2011 |
| Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies AD Cohen, S Parekh, BD Santomasso, J Gállego Pérez-Larraya, ... Blood cancer journal 12 (2), 32, 2022 | 95 | 2022 |
| Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma AM Petrich, V Leshchenko, PY Kuo, B Xia, VK Thirukonda, N Ulahannan, ... Clinical Cancer Research 18 (9), 2534-2544, 2012 | 84 | 2012 |
